Summary
DexCom, Inc. (DXCM) filed an 8-K on February 21, 2013, reporting two key events. The company terminated a material definitive agreement with Roche Diagnostics Operations, Inc. concerning the integration of DexCom's continuous glucose monitoring (CGM) technology with Roche's Accu-Chek® insulin delivery system in the U.S. This termination was due to development timelines becoming extended and more costly than initially anticipated, despite DexCom receiving some milestone and development expense offset payments. Additionally, DexCom issued a press release on February 21, 2013, announcing its financial results for the year ended December 31, 2012, which is furnished as an exhibit to this report.
Key Highlights
- 1Termination of Material Definitive Agreement: DexCom and Roche Diagnostics Operations, Inc. have mutually terminated their Research and Development Agreement dated November 1, 2011.
- 2Agreement Scope: The terminated agreement focused on integrating DexCom's future generation CGM technology with Roche's next-generation Accu-Chek® insulin delivery system for the U.S. market.
- 3Financial Impact of Termination: DexCom received a total of $1.1 million from Roche for milestone payments and $0.1 million to offset development expenses under the terminated agreement.
- 4Reason for Termination: Extended and more costly development timelines for integrating DexCom's G4 Platinum or next-generation CGM systems with the Roche product led to the termination.
- 5Continued Partnership: DexCom and Roche will continue to work together under their existing distribution arrangements.
- 6Financial Results Announcement: DexCom issued a press release on February 21, 2013, detailing its financial results for the fiscal year ended December 31, 2012.
Frequently Asked Questions
The agreement was terminated because the development timelines to integrate DexCom's CGM technology with Roche's insulin delivery system became extended and more costly than originally anticipated by both parties.
Yes, DexCom received an initial payment of $0.5 million upon execution, an additional $0.5 million as part of milestone payments, and $0.1 million to offset development expenses, totaling $1.1 million in payments received.
No, the filing states that DexCom and Roche will continue to work together under their existing distribution arrangements, meaning the termination was specific to the R&D integration project, not broader distribution.
In addition to reporting the termination of the agreement, DexCom also announced its financial results for the year ended December 31, 2012, through a press release furnished as part of this 8-K filing.